Futura leverages proprietary DermaSys transdermal delivery technology for topically applied products. Despite securing commercial partnerships with Cooper Consumer Health (EU) and Haleon (US), the company has faced significant commercialization challenges, with Eroxon failing to achieve expected market traction despite regulatory wins.
Cyborg Score Rationale
The company faces severe commercial headwinds with Eroxon sales substantially underperforming expectations, stock down 96% in 2025, and significant cash constraints requiring emergency fundraising. Market adoption has been poor despite regulatory approvals and partnership agreements.
Top Insights
Stock collapsed 96% in 2025 despite EU/US regulatory approvals for lead product Eroxon, signaling commercialization execution problems
H1 2025 sales of £1.0m vs £3.8m prior year; full-year projection at only £1.3-£1.4m indicates severe market adoption failure
Negative consumer reviews and sentiment on social media have severely undermined product uptake despite strong channel partnerships
New CEO Alex Duggan appointed to lead turnaround; company faces potential exit of Haleon relationship and existential cash runway concerns
Named Competitors
Oral erectile dysfunction treatments — Established oral pharmaceutical alternatives
Topical ED products — Emerging topical competitors in sexual health
Recent Developments
(September 2025) Trading statement revealed only £1.3-1.4m full year sales projection, well below expectations
(Q3 2025) Emergency fundraise of £2.75m due to severe cash constraints